Browse Tag

Obesity

3 Articles

Scientific illustration of Leaderna Therapeutics’ siRNA drug platform targeting cardiometabolic diseases including hypertension, obesity and hyperlipidemia through RNA-based therapies.

Leaderna Therapeutics Completes Series A+ Financing to Advance Small Nucleic Acid Drug Pipeline

By Chris Chen

6 Min Read

Chengdu-based Leaderna Therapeutics has completed a Series A+ financing round backed exclusively by Grand View Capital, adding fresh capital to accelerate clinical development of its small nucleic acid drug pipeline and further develop its extrahepatic…

Scientific illustration of Ascletis’ ASC30 once-daily oral small-molecule GLP-1 receptor agonist, showing GLP-1 receptor binding, appetite and gastrointestinal effects, weight reduction and global Phase III clinical development.

Ascletis Doses First Participant in Global Phase III Program of Oral GLP-1 Drug ASC30

By Xiaoxin Du

No Comments

8 Min Read

Ascletis Pharma has dosed the first participant in its global Phase III AURORA clinical program evaluating ASC30, a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management, launching a roughly 4,600-patient registrational…

Illustration of Innovent Biologics’ IBI3042, a once-weekly oral GLP-1 receptor agonist, showing oral absorption, GLP-1 receptor activation and potential effects on weight loss, blood glucose and appetite.

Innovent’s Once-Weekly Oral GLP-1 IBI3042 Gets NMPA IND Clearance for Obesity

By Henry Tseng

No Comments

6 Min Read

Innovent Biologics has received clearance from China’s National Medical Products Administration (NMPA) to begin clinical development of IBI3042, a potentially first-in-class once-weekly oral small-molecule GLP-1 receptor agonist, marking another…